金城醫藥(300233.SZ):富馬酸比索洛爾膠囊(5mg、10mg)獲藥品補充申請批件
格隆匯 6 月 22日丨金城醫藥(300233.SZ)公佈,公司於2020年6月22日收到全資子公司北京金城泰爾製藥有限公司(“金城泰爾”)的通知,其獲得了國家藥品監督管理局下發的藥品補充申請批件。經審查,金城泰爾申報的富馬酸比索洛爾膠囊(5mg、10mg)符合《中華人民共和國藥品管理法》的有關規定,批准修訂説明書相關內容。
富馬酸比索洛爾膠囊主要適用於高血壓、冠心病(心絞痛)的治療。
公司上述藥品補充申請批件的取得短期內不會對公司的財務狀況、經營業績構成重大影響。上述產品的具體經營情況受到市場環境變化等不確定因素影響,具有不確定性,請廣大投資者謹慎決策,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.